Syngene International Ltd. · NSE:SYNGENE
Syngene International — Q3 FY26 Earnings Presentation
31 slides from Syngene International's earnings presentation, January 2026
Slide 1: Investor Presentation
Investor Presentation January 2026
Slide 2: Safe harbour
Safe harbour Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements
Slide 3: Contents
Contents 1 Q3 FY26 Highlights 2 Syngene – Putting Science to Work 3 Syngene strengths 4 Financials 5 Shareholding and Share Information Putting Science to Work 3
Slide 4: Q3 FY26 Highlights
1 Q3 FY26 Highlights Syngene
Slide 5: Q3 and 9M FY26 performance
Q3 and 9M FY26 performance Operating Highlights Q3 FY26 Financial Highlights ▪ Bristol Myers Squibb (BMS) has extended its long-standing partnership with Syngene through to 2035. The expanded agreement broadens the scope of Revenue from Operations Operating EBITDA margin integrated services across t
Slide 6: Syngene – Putting Science to Work
2 Syngene – Putting Science to Work
Slide 7: Partner in innovation: Putting Science to Work
Partner in innovation: #Putting Science to Work Who we are and what we do We aim to be a world class partner delivering innovative scientific solutions for clients We offer integrated Sector expertise include Our team includes more than Established track record in solutions across pharmaceuticals, b
Slide 8: Our journey so far
Our journey so far 2019 – 2025 Globalization and strategic collaboration Continued investments and growth • Expanded collaboration with BMS, Amgen and • Expanded into formulations development Zoetis • Contract with Endo Pharmaceuticals to develop novel anti cancer • Expansion of Integrated Drug Disc
Slide 9: Key facts and figures
Key facts and figures ~400 14 out of top 20 400+ World class infrastructure active clients pharma companies are patents International presence with global clients held with clients campuses across Bangalore, Hyderabad and Mangalore in India and Baltimore in USA qualified to meet international standa
Slide 10: Syngene – one of the largest integrated CRDMO players in India
Syngene – one of the largest integrated CRDMO players in India One-stop platform for integrated drug discovery, development and manufacturing across modalities Expanding capacity Building capabilities for future Building partnerships (in Million sq. ft.) (#) (#) 2.5+ 8,235 ~400 0.9 3,526 250+ March’
Slide 11: 3-pronged growth strategy across diversified platform
3-pronged growth strategy across diversified platform Research Services (CRO) Large Molecule CDMO Small Molecule CDMO Discovery Services Dedicated R&D Centers Clinical Development Flexible Platform with capability Ring-fenced infrastructure for Comprehensive research services Process development Dru
Slide 12: Our Strategy
Our Strategy Research Services Development and Development and Manufacturing Services – Manufacturing Services – Provide an integrated end-to-end Large Molecules Small Molecules therapeutic discovery services Encompassing drug discovery, pre- Utilize existing Chemistry, Manufacturing, Implement a co
Slide 13: Syngene strengths
3 Syngene strengths Syngene
Slide 14: Syngene strengths
Syngene strengths A global scale CRDMO player Solutions through innovation Quality matters • Integrated Drug Discovery, Development and • IP fully assigned to clients • Fully digitized quality organization Manufacturing service provider • Track record of data management and • Strong compliance track
Slide 15: Experienced workforce: building capabilities and careers
Experienced workforce: building capabilities and careers 8,235 Inspiring technical excellence and providing opportunities to grow total headcount • Thrive 360: A holistic approach to employee well being addressing physical, mental and emotional, social, financial and professional health through targ
Slide 16: Extended our state-of-the-art infrastructure & new capabilities with global presence
Extended our state-of-the-art infrastructure & new capabilities with global presence to meet our strategic partners needs… USA based Biologics facility HQ campus at Bangalore, India Fully functional Bayview, Baltimore, 90 Acres (3,64,217 sq. mt) where most of R&D Centre at USA Syngene’s capabilities
Slide 17: We currently operate a range of successful collaboration models
We currently operate a range of successful collaboration models Dedicated R&D Labs • Customers receive ring-fenced infrastructure customized to Full time equivalent (FTE) • A dedicated team of scientific personnel from predefined Fee For service (FFS) • Services are provided within a defined scope R
Slide 18: Our experience spans multiple industry segments and global leaders
Our experience spans multiple industry segments and partners us with global leaders across the world… Large & Mid-Sized Emerging Chemicals/ BioPharma BioPharma (EBP) Animal Health AgroChem CPG Polymers Note : This is a representative selection of the customers Syngene works with. We work with ~ 400
Slide 19: Operational robustness driving strategy execution
Operational robustness driving strategy execution Continuous improvement embedded in operations driven by Focused execution through strong Project certified operational leaders Management Six Sigma Black Belt certified staff in each Structured program management for executing client service line and
Slide 20: Syngene digital initiatives aimed at driving innovation and operational excellence
Syngene digital initiatives aimed at driving innovation and operational At Syngene, IT strategy is closely aligned with organizational priorities, emphasizing investments in automation and digitization to improve Certification as per ISO 13485:2016, ISO/IEC scientific and enterprise functions. 27001
Slide 21: Committed to safety and sustainability
Committed to safety and sustainability Committed to environmental protection Safety is our first priority • Committed to Science-based targets for greenhouse gases • Accredited with ISO 45001:2018 for Occupational • 95% of total hazardous and non-hazardous Health and Safety (OH&S) waste recycled mea
Slide 22: Accreditations
Accreditations • USFDA, EMA, UK VMD, PMDA and Health Canada Certified GMP facilities. • GLP, NABL (ISO IEC 17025) certification for Safety Assessment and Large Molecule Bioanalytical Laboratory • GLP certification for Viral Testing Facility, AAALAC Accreditation and CCSEA registration for Safety Ass
Slide 23: Industry recognition for scientific capability and business excellence
We have consistently received industry recognition for our scientific capability and business excellence • CMO Leadership Awards 2022 Presented by Life Science Leader and Outsourced Pharma • EcoVadis Sustainability Rating, 2024 : Syngene secured silver rating in the EcoVadis sustainability index for
Slide 24: Robust risk management framework
Robust risk management framework Syngene’s enterprise-wide risk management framework provides a holistic approach to identification, monitoring, reporting and mitigating risks that could impact performance. Risk Management Board of Directors Risk Owner Executive Committee Committee (BOD) • Continuou
Slide 25: Financials
4 Financials
Slide 26: Q3 FY26 financial highlights
Q3 FY26 financial highlights All figures in Rs. Mn unless otherwise specified Balance Sheet Highlights Particulars Q3FY26 Q3 FY25 YoY change Q2 FY26 QoQ change Revenue from operations 9,171 9,437 -3% 9,106 1% As on 31st December 2025 All figures in Rs. Mn unless otherwise specified Other income 154
Slide 27: 9M FY26 financial highlights
9M FY26 financial highlights All figures in Rs. Mn unless otherwise specified Particulars 9M FY25 9M FY26 YoY change Revenue from operations 26,244 27,022 3% Other income 529 485 -8% Reported revenue 26,773 27,507 3% Material costs 7,075 6,860 -3% Staff costs 7,999 8,981 12% Other direct costs 7
Slide 28: Shareholding and Share Information
Shareholding and Share 5 Information
Slide 29: Syngene and Biocon Group
Syngene and Biocon Group Syngene is an operationally independent publicly listed Biocon Limited, founded in 1978, is an innovation-led global subsidiary of Biocon Limited, established in 1993 as India’s biopharmaceuticals company and has majority holding in key first Contract Research Organization.
Slide 30: Shareholding and Share Information
Shareholding and Share Information Syngene’s shareholders* Syngene’s Share Information* NSE Ticker SYNGENE 1% BSE Ticker 539268 Promoter & Promoter Group Market Cap (Rs. Mn) 2,62,314 47% 53% Public % free-float^ 47% ESOP Trust Free-float market cap (Rs. Mn) 1,24,117 Share Outstanding (Mn) 403 • As o
Slide 31: For more details
For more details Visit our website www.syngeneintl.com https://www.linkedin.com/company/syngene-international-limited https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ IR Contact: Media Contact: Nandini Agarwal / Shubham Jain Vijay Jeevanandham investor@syngeneintl.com E: Vijay.jeevanandham@s
Syngene International — Q3 FY26 Earnings Presentation on 6ix